Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shantha Bio, PATH to Develop Rotavirus Vaccine (India)

This article was originally published in PharmAsia News

Executive Summary

Shantha Biotechnics in India is developing a multivalent vaccine against rotavirus as part of a partnership with PATH, the global nonprofit health organization, and the National Institutes of Health. The parties are pursuing the accelerated development of a new vaccine that is safe, effective, and affordable. Licensed vaccines for rotavirus include Merck's RotaTeq and GSK's Rotatrix, but they are not available in the country at present. Shantha will be using technology licensed from the United States. The completion of preclinical toxicology studies will be followed by clinical trials in 2008. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel